ABBYAbby, Inc.
The schedule
- Thu15Oct
Expected deadline for toxic debt conversion or a highly dilutive capital raise to stave off immediate insolvency.
- Fri13Nov
Q3 2026 estimated results and potential announcement of strategic alternatives or reverse merger.
- Fri27Nov
- Mon15Feb
Deadline for potential SEC action regarding delinquent filings or registration revocation.
- Fri26Feb
- Fri28May
- Fri27Aug
Past
- Fri28Aug
Actual outcome: Mixed · $0.00 at outcome
Price at outcome date was between bear floor ($0.00) and bull target ($0.00).
Estimated Q2 2026 earnings filing evaluating the company's survival and going-concern status.
- Fri21Aug
Actual outcome: Bull · $0.00 at outcome
AbbVie reported 10.2% top-line growth and 22.9% adjusted diluted EPS growth in Q2, with management raising 2026 revenue guidance by $300 million. The strong results and optimistic outlook for the year significantly boosted investor confidence and drove the stock higher. [Market retrospective · Long-Term (31–75 days)] Missed anticipation: +3900.0% from 2026-05-01 to 2026-08-20 (~7.6σ vs typical 75d vol). Target evaluation date 2026-09-21 (not yet reached as of 2026-08-20). Confidence 95%.
AbbVie reported 10.2% top-line growth and 22.9% adjusted diluted EPS growth in Q2, with management raising 2026 revenue guidance by $300 million. The strong results and optimistic outlook for the year significantly boosted investor confidence and drove the stock higher. [Market retrospective · Long-Term (31–75 days)] Missed anticipation: +3900.0% from 2026-05-01 to 2026-08-20 (~7.6σ vs typical 75d vol). Target evaluation date 2026-09-21 (not yet reached as of 2026-08-20). Confidence 95%.